TD Asset Management Inc Reduces Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

TD Asset Management Inc reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 29.2% in the third quarter, HoldingsChannel reports. The firm owned 312,517 shares of the biopharmaceutical company’s stock after selling 128,660 shares during the quarter. TD Asset Management Inc’s holdings in Alnylam Pharmaceuticals were worth $142,508,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in ALNY. Greenland Capital Management LP grew its position in Alnylam Pharmaceuticals by 95.9% during the third quarter. Greenland Capital Management LP now owns 1,959 shares of the biopharmaceutical company’s stock valued at $893,000 after buying an additional 959 shares during the period. Compound Planning Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 41.2% during the 3rd quarter. Compound Planning Inc. now owns 942 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 275 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 158.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,130 shares of the biopharmaceutical company’s stock valued at $515,000 after acquiring an additional 693 shares during the period. Private Advisory Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $647,000. Finally, Alliance Wealth Advisors LLC UT bought a new position in Alnylam Pharmaceuticals in the 3rd quarter worth $230,000. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ALNY. HC Wainwright reissued a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 18th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Barclays assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price objective for the company. Chardan Capital decreased their target price on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Finally, Royal Bank Of Canada dropped their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $477.96.

Insider Buying and Selling

In other news, EVP Jeffrey V. Poulton sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president owned 59,802 shares in the company, valued at $18,543,404.16. This trade represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Pushkal Garg sold 2,242 shares of the business’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the sale, the executive vice president owned 24,848 shares in the company, valued at $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,578 shares of company stock worth $12,416,105 in the last 90 days. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Down 1.6%

NASDAQ ALNY opened at $327.44 on Thursday. The stock’s 50 day moving average is $363.18 and its 200 day moving average is $420.28. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The stock has a market cap of $43.42 billion, a PE ratio of 191.48 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s quarterly revenue was up 84.9% compared to the same quarter last year. During the same period last year, the business earned ($0.65) earnings per share. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.